本帖最后由 老马 于 2013-3-13 13:43 编辑 9 ]( E' G, i% M3 i4 L
% X; |- ^: G* W# {/ D8 H健择（吉西他滨）+顺铂+阿瓦斯汀# E; e& O' I! F- n
Gemzar +Cisplatin + Avastin$ c0 }3 ~' r5 e5 c) {' a3 }) Y
http://annonc.oxfordjournals.org/content/21/9/1804.full' C& }. l) O' j$ F+ d: U
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% A: w; S* p) {: p0 a( gPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 r9 K6 _# |' L: f9 v9 hResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. & V( V+ T6 ]2 r( h( w
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 807)
" x2 c9 O4 U! c; R华为网盘附件：! k [1 T- K4 m" }# I; n+ W5 ]
【华为网盘】ava.JPG4 y# {0 [1 L) `1 O6 A
|
显身卡
